Skip Navigation LinksHome > May 2013 - Volume 51 - Issue 5 > Identifying Specific Chemotherapeutic Agents in Medicare Dat...
Text sizing:
A
A
A
Medical Care:
doi: 10.1097/MLR.0b013e31823ab60f
Applied Methods

Identifying Specific Chemotherapeutic Agents in Medicare Data: A Validation Study

Lund, Jennifer L. MSPH*; Stürmer, Til MD, PhD*; Harlan, Linda C. PhD; Sanoff, Hanna K. MD, MPH; Sandler, Robert S. MD, MPH§; Brookhart, Maurice Alan PhD*; Warren, Joan L. PhD

Supplemental Author Material
Collapse Box

Abstract

Background: Large health care databases are increasingly used to examine the dissemination and benefits and harms of chemotherapy treatment in routine practice, particularly among patients excluded from trials (eg, the elderly). Misclassification of chemotherapy could bias estimates of frequency and association, warranting an updated assessment.

Methods: We evaluated the validity of Medicare claims to identify receipt of chemotherapy and specific agents delivered to elderly stage II/III colorectal (CRC), in situ/early-stage breast, non-small–cell lung, and ovarian cancer patients using the National Cancer Institute’s Patterns of Care studies (POC) as the gold standard. The POC collected data on chemotherapy treatment by reabstracting hospital records, contacting physicians, and reviewing medical records. Patients’ POC data were linked and compared with their Medicare claims for 2 to 12 months postdiagnosis. κ, sensitivity, specificity, positive and negative predictive values and 95% confidence intervals were calculated for the receipt of any chemotherapy and specific agents.

Results: Sensitivity and specificity of Medicare claims to identify any chemotherapy were high across all cancer sites. We found substantial variation in validity across agents, by site and administration modality. Capecitabine, an oral CRC treatment, was identified in claims with high specificity (98%) but low sensitivity (47%), whereas oxaliplatin, an intravenously administered CRC agent had higher sensitivity (75%) and similar specificity (97%).

Conclusions: Receipt of chemotherapy and specific intravenous agents can be identified using Medicare claims, showing improvement from prior reports; yet, variation exists. Future studies should assess newly approved agents and the impact of coverage decisions for these agents under the Medicare Part D program.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.